<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668484</url>
  </required_header>
  <id_info>
    <org_study_id>GEMucS001-15</org_study_id>
    <nct_id>NCT02668484</nct_id>
  </id_info>
  <brief_title>REpositionable Versus BallOOn-expandable Prosthesis for Trans-catheter Aortic Valve Implantation</brief_title>
  <acronym>REBOOT</acronym>
  <official_title>Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are different aortic valve prosthesis used for treatment of aortic valve disease
      through catheter-based procedures. The current study aims to compare two different aortic
      valve prosthesis regarding their outcomes at 30-day and 2-year follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Important improvements in aortic valve prostheses technology has been made aiming comparable
      performance of these prosthesis to surgical valve ones.

      The experience with the early generation of aortic valve prostheses revealed some important
      differences regarding the incidence of paravalvular leakage, need for pacemaker or valve
      thrombosis among them. Currently the new generations of valve prostheses such as Sapien 3
      balloon-expandable valve and Lotus, repositionable valve are the most frequently used
      devices. There are registry data about the clinical performance of these valve types but a
      randomized comparison is missing.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of new permanent pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any prosthesis regurgitation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any conduction abnormalities</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success according to VARC-2 definition</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early safety parameters according to VARC-2 definitions</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined efficacy according to VARC-2 definitions</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined efficacy according to VARC-2 definitions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>repositionable valve prosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>balloon-expandable valve prosthesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sapien</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repositionable valve prosthesis</intervention_name>
    <description>repositionable valve prosthesis implanted via trans-femoral and trans-catheter route</description>
    <arm_group_label>repositionable valve prosthesis</arm_group_label>
    <other_name>Lotus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balloon-expandable valve prosthesis</intervention_name>
    <description>balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route</description>
    <arm_group_label>balloon-expandable valve prosthesis</arm_group_label>
    <other_name>Sapien</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic aortic valve disease in need of valve replacement

          2. Heart team (including at least a cardiac surgeon and an interventional cardiologist)
             agrees on the eligibility that trans-femoral TAVI is appropriate.

          3. Study patient is an adult of legal consent age.

          4. Study patient has provided written informed consent to participate in the study

        Exclusion Criteria:

          1. Life expectancy &lt; 12 months due to co-morbid conditions.

          2. Native aortic valve annulus size and morphology not suitable for Lotus or Sapien
             prosthesis implantation

          3. Preexisting bioprosthetic valve or ring in aortic valve position.

          4. Pre-existing pacemaker or ICD/CRT.

          5. Cardiogenic shock or hemodynamic instability.

          6. History of active endocarditis

          7. Contraindications for a trans-femoral access.

          8. Severe left ventricular dysfunction with LVEF &lt;30%.

          9. Severe mitral valve insufficiency.

         10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

         11. Patients actively participating in another drug or device investigational study and
             have not yet completed the primary endpoint follow-up period.

         12. Patients suffering from dementia.

         13. Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Clinic, Ludwig-Maximilians University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Munich University Clinic, Ludwig-Maximilians University</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken Gmbh</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Julinda Mehilli</investigator_full_name>
    <investigator_title>Director, Interventional Cardiology</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>trans-femoral</keyword>
  <keyword>Sapien</keyword>
  <keyword>Lotus</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

